Assessment of Oxygen Supply-Demand Imbalance and Outcomes Among Patients With Type 2 Myocardial Infarction: A Secondary Analysis of the High-STEACS Cluster Randomized Clinical Trial

Anda Bularga, Caelan Taggart, Filip Mendusic, Dorien M Kimenai, Ryan Wereski, Matthew T H Lowry, Kuan K Lee, Amy V Ferry, Stacey S Stewart, David A McAllister, Anoop S V Shah, Atul Anand, David E Newby, Nicholas L Mills, Andrew R Chapman, High-Sensitivity Troponin in the Evaluation of Patients with Suspected Acute Coronary Syndrome (High-STEACS) Investigators, Fiona E Strachan, Christopher Tuck, Dimitrios Doudesis, Dennis Sandeman, Philip D Adamson, Jack P M Andrews, Alastair Moss, Mohamed S Anwar, John Hung, Catherine L Stables, Catalina A Vallejo, Athanasios Tsanas, Lucy Marshal, Takeshi Fujisawa, Mischa Hautvast, Jean McPherson, Lynn McKinley, Keith A A Fox, Colin Berry, Simon Walker, Christopher Weir, Ian Ford, Alasdair Gray, Paul O Collinson, Fred S Apple, Alan Reid, Anne Cruikshank, Iain Findlay, Shannon Amoils, Donogh Maguire, Jennifer Stevens, John Norrie, Jonathan Malo, Colin M Fischbacher, Bernard L Croal, Stephen J Leslie, Catriona Keerie, Richard A Parker, Allan Walker, Ronnie Harkess, Tony Wackett, Roma Armstrong, Marion Flood, Laura Stirling, Claire MacDonald, Imran Sadat, Frank Finlay, Heather Charles, Pamela Linksted, Stephen Young, Bill Alexander, Chris Duncan, Anda Bularga, Caelan Taggart, Filip Mendusic, Dorien M Kimenai, Ryan Wereski, Matthew T H Lowry, Kuan K Lee, Amy V Ferry, Stacey S Stewart, David A McAllister, Anoop S V Shah, Atul Anand, David E Newby, Nicholas L Mills, Andrew R Chapman, High-Sensitivity Troponin in the Evaluation of Patients with Suspected Acute Coronary Syndrome (High-STEACS) Investigators, Fiona E Strachan, Christopher Tuck, Dimitrios Doudesis, Dennis Sandeman, Philip D Adamson, Jack P M Andrews, Alastair Moss, Mohamed S Anwar, John Hung, Catherine L Stables, Catalina A Vallejo, Athanasios Tsanas, Lucy Marshal, Takeshi Fujisawa, Mischa Hautvast, Jean McPherson, Lynn McKinley, Keith A A Fox, Colin Berry, Simon Walker, Christopher Weir, Ian Ford, Alasdair Gray, Paul O Collinson, Fred S Apple, Alan Reid, Anne Cruikshank, Iain Findlay, Shannon Amoils, Donogh Maguire, Jennifer Stevens, John Norrie, Jonathan Malo, Colin M Fischbacher, Bernard L Croal, Stephen J Leslie, Catriona Keerie, Richard A Parker, Allan Walker, Ronnie Harkess, Tony Wackett, Roma Armstrong, Marion Flood, Laura Stirling, Claire MacDonald, Imran Sadat, Frank Finlay, Heather Charles, Pamela Linksted, Stephen Young, Bill Alexander, Chris Duncan

Abstract

Importance: Type 2 myocardial infarction occurs owing to multiple factors associated with myocardial oxygen supply-demand imbalance, which may confer different risks of adverse outcomes.

Objective: To evaluate the prevalence and outcomes of different factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction.

Design, setting, and participants: In this secondary analysis of a stepped-wedge, cluster randomized clinical trial conducted at 10 secondary and tertiary care hospitals in Scotland, 6096 patients with an adjudicated diagnosis of type 1 or type 2 myocardial infarction from June 10, 2013, to March 3, 2016, were identified, and the findings were reported on August 28, 2018. The trial enrolled consecutive patients with suspected acute coronary syndrome. The diagnosis of myocardial infarction was adjudicated according to the Fourth Universal Definition of Myocardial Infarction and the primary factor associated with oxygen supply-demand imbalance in type 2 myocardial infarction was defined. This secondary analysis was not prespecified. Statistical analysis was performed from July 7 to 30, 2020.

Intervention: Implementation of a high-sensitivity cardiac troponin I assay.

Main outcomes and measures: All-cause death at 1 year according to the factors associated with oxygen supply-demand imbalance among patients with type 2 myocardial infarction.

Results: Of 6096 patients (2602 women [43%]; median age, 70 years [IQR, 58-80 years]), 4981 patients had type 1 myocardial infarction, and 1115 patients had type 2 myocardial infarction. The most common factor associated with oxygen supply-demand imbalance was tachyarrhythmia (616 of 1115 [55%]), followed by hypoxemia (219 of 1115 [20%]), anemia (95 of 1115 [9%]), hypotension (89 of 1115 [8%]), severe hypertension (61 of 1115 [5%]), and coronary mechanisms (35 of 1115 [3%]). At 1 year, all-cause mortality occurred for 15% of patients (720 of 4981) with type 1 myocardial infarction and 23% of patients (285 of 1115) with type 2 myocardial infarction. Compared with patients with type 1 myocardial infarction, those with type 2 myocardial infarction owing to hypoxemia (adjusted odds ratio [aOR], 2.35; 95% CI, 1.72-3.18) and anemia (aOR, 1.83; 95% CI, 1.14-2.88) were at greatest risk of death, whereas those with type 2 myocardial infarction owing to tachyarrhythmia (aOR, 0.83; 95% CI, 0.65-1.06) or coronary mechanisms (aOR, 1.07; 95% CI, 0.17-3.86) were at similar risk of death as patients with type 1 myocardial infarction.

Conclusions and relevance: In this secondary analysis of a randomized clinical trial, mortality after type 2 myocardial infarction was associated with the underlying etiologic factor associated with oxygen supply-demand imbalance. Most type 2 myocardial infarctions were associated with tachyarrhythmia, with better prognosis, whereas hypoxemia and anemia accounted for one-third of cases, with double the mortality of type 1 myocardial infarction. These differential outcomes should be considered by clinicians when determining which cases need to be managed if patient outcomes are to improve.

Trial registration: ClinicalTrials.gov Identifier: NCT01852123.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Wereski reported receiving grants from the British Heart Foundation during the conduct of the study and grants from the Medical Research Council outside the submitted work. Dr Shah reported receiving personal fees from Abbott Diagnostics to the institution during the conduct of the study. Dr Anand reported receiving a consultancy fee from AbbVie Ltd outside the submitted work. Dr Mills reported receiving grants and personal fees from Abbott Diagnostics and Siemens Healthineers and personal fees from Roche and LumiraDx outside the submitted work. No other disclosures were reported.

Figures

Figure 1.. Trial Population
Figure 1.. Trial Population
UDMI indicates Universal Definition of Myocardial Infarction.
Figure 2.. Factors Associated With Oxygen Supply-Demand…
Figure 2.. Factors Associated With Oxygen Supply-Demand Imbalance in Type 2 Myocardial Infarction (MI)
A, Cumulative incidence curve for the primary outcome of all-cause death at 1 year. B, Kernel density plot showing the distribution of maximal high-sensitivity cardiac troponin I concentrations (ng/L [to convert to micrograms per liter, multiply by 0.001]) according to adjudicated diagnosis and factors associated with oxygen supply-demand imbalance in type 2 myocardial infarction (MI).
Figure 3.. Outcomes According to the Factors…
Figure 3.. Outcomes According to the Factors Associated With Myocardial Infarction
A, Cumulative incidence curves for the primary outcome of all-cause death at 1 year. B, Cumulative incidence curves for the secondary outcomes of myocardial infarction or cardiovascular death. C, Cumulative incidence curves for noncardiovascular death. The “coronary mechanisms” category includes patients with myocardial infarction owing to coronary artery plaque rupture or erosion (type 1) and coronary artery dissection, embolism, or vasospasm (type 2); the “systemic illnesses” category includes patients with myocardial infarction in response to an acute systemic illness, such as anemia, hypotension, hypoxemia, and severe hypertension. Patients with myocardial infarction owing to primary tachyarrhythmia comprise the “tachyarrhythmias” category.

References

    1. Thygesen K, Alpert JS, White HD, et al. ; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction . Universal definition of myocardial infarction. Circulation. 2007;116(22):2634-2653. doi:10.1161/CIRCULATIONAHA.107.187397
    1. Thygesen K, Alpert JS, Jaffe AS, et al. ; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG) . Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-2567. doi:10.1093/eurheartj/ehs184
    1. Thygesen K, Alpert JS, Jaffe AS, et al. ; ESC Scientific Document Group . Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J. 2019;40(3):237-269. doi:10.1093/eurheartj/ehy462
    1. Shah AS, McAllister DA, Mills R, et al. . Sensitive troponin assay and the classification of myocardial infarction. Am J Med. 2015;128(5):493-501.e3. doi:10.1016/j.amjmed.2014.10.056
    1. Chapman AR, Adamson PD, Shah ASV, et al. ; High-STEACS Investigators . High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation. 2020;141(3):161-171. doi:10.1161/CIRCULATIONAHA.119.042960
    1. Saaby L, Poulsen TS, Hosbond S, et al. . Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126(9):789-797. doi:10.1016/j.amjmed.2013.02.029
    1. Sandoval Y, Smith SW, Sexter A, et al. . Type 1 and 2 myocardial infarction and myocardial injury: clinical transition to high-sensitivity cardiac troponin I. Am J Med. 2017;130(12):1431-1439. doi:10.1016/j.amjmed.2017.05.049
    1. DeFilippis AP, Chapman AR, Mills NL, et al. . Assessment and treatment of patients with type 2 myocardial infarction and acute non-ischemic myocardial injury. Circulation. 2019;140(20):1661-1678. doi:10.1161/CIRCULATIONAHA.119.040631
    1. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study group . Type 2 myocardial infarction in clinical practice. Heart. 2015;101(2):101-106. doi:10.1136/heartjnl-2014-306093
    1. Reid C, Alturki A, Yan A, et al. . Meta-analysis comparing outcomes of type 2 myocardial infarction and type 1 myocardial infarction with a focus on dual antiplatelet therapy. CJC Open. 2020;2(3):118-128. doi:10.1016/j.cjco.2020.02.005
    1. Sandoval Y, Jaffe AS. Type 2 myocardial infarction: JACC review topic of the week. J Am Coll Cardiol. 2019;73(14):1846-1860. doi:10.1016/j.jacc.2019.02.018
    1. Chapman AR, Shah ASV, Lee KK, et al. . Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury. Circulation. 2018;137(12):1236-1245. doi:10.1161/CIRCULATIONAHA.117.031806
    1. Chapman AR, Sandoval Y. Type 2 myocardial infarction: evolving approaches to diagnosis and risk-stratification. Clin Chem. 2021;67(1):61-69. doi:10.1093/clinchem/hvaa189
    1. Collet JP, Barbato E. The “Ten Commandments” for the 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;41(37):3495-3497. doi:10.1093/eurheartj/ehaa624
    1. Raphael CE, Roger VL, Sandoval Y, et al. . Incidence, trends, and outcomes of type 2 myocardial infarction in a community cohort. Circulation. 2020;141(6):454-463. doi:10.1161/CIRCULATIONAHA.119.043100
    1. Shah ASV, Anand A, Strachan FE, et al. ; High-STEACS Investigators . High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018;392(10151):919-928. doi:10.1016/S0140-6736(18)31923-8
    1. Shah ASV, Griffiths M, Lee KK, et al. . High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873. doi:10.1136/bmj.g7873
    1. Sandoval Y, Smith SW, Sexter A, Schulz K, Apple FS. Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury. Eur Heart J Acute Cardiovasc Care. 2020;9(1):62-69. doi:10.1177/2048872618787796
    1. Patterson C, Maclean F, Bell C, et al. . Early warning systems in the UK: variation in content and implementation strategy has implications for a NHS early warning system. Clin Med (Lond). 2011;11(5):424-427. doi:10.7861/clinmedicine.11-5-424
    1. Fox KAA, Dabbous OH, Goldberg RJ, et al. . Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091. doi:10.1136/bmj.38985.646481.55
    1. Singh A, Gupta A, DeFilippis EM, et al. . Cardiovascular mortality after type 1 and type 2 myocardial infarction in young adults. J Am Coll Cardiol. 2020;75(9):1003-1013. doi:10.1016/j.jacc.2019.12.052
    1. Mariathas M, Allan R, Ramamoorthy S, et al. . True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ. 2019;364:l729. doi:10.1136/bmj.l729
    1. Furie N, Israel A, Gilad L, et al. . Type 2 myocardial infarction in general medical wards: clinical features, treatment, and prognosis in comparison with type 1 myocardial infarction. Medicine (Baltimore). 2019;98(41):e17404. doi:10.1097/MD.0000000000017404
    1. Carroll I, Mount T, Atkinson D. Myocardial infarction in intensive care units: a systematic review of diagnosis and treatment. J Intensive Care Soc. 2016;17(4):314-325. doi:10.1177/1751143716656642
    1. McCarthy CP, Olshan DS, Rehman S, et al. . Cardiologist evaluation of patients with type 2 myocardial infarction. Circ Cardiovasc Qual Outcomes. 2021;14(1):e007440. doi:10.1161/CIRCOUTCOMES.120.007440
    1. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction: should we be paying more attention? J Am Coll Cardiol. 2014;63(20):2079-2087. doi:10.1016/j.jacc.2014.02.541
    1. Januzzi JL, Sandoval Y. The many faces of type 2 myocardial infarction. J Am Coll Cardiol. 2017;70(13):1569-1572. doi:10.1016/j.jacc.2017.07.784
    1. Gaggin HK, Liu Y, Lyass A, et al. . Incident type 2 myocardial infarction in a cohort of patients undergoing coronary or peripheral arterial angiography. Circulation. 2017;135(2):116-127. doi:10.1161/CIRCULATIONAHA.116.023052
    1. Thygesen K, Jaffe AS. The gloomy long-term prognosis of patients with type 2 myocardial infarction or myocardial injury. J Am Coll Cardiol. 2020;75(9):1014-1016. doi:10.1016/j.jacc.2020.01.004
    1. Nestelberger T, Boeddinghaus J, Badertscher P, et al. ; APACE Investigators . Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol. 2017;70(13):1558-1568. doi:10.1016/j.jacc.2017.07.774
    1. Saaby L, Poulsen TS, Diederichsen AC, et al. . Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med. 2014;127(4):295-302. doi:10.1016/j.amjmed.2013.12.020
    1. Lambrecht S, Sarkisian L, Saaby L, et al. . Different causes of death in patients with myocardial infarction type 1, type 2, and myocardial injury. Am J Med. 2018;131(5):548-554. doi:10.1016/j.amjmed.2017.11.043
    1. Rothnie KJ, Quint JK. Chronic obstructive pulmonary disease and acute myocardial infarction: effects on presentation, management, and outcomes. Eur Heart J Qual Care Clin Outcomes. 2016;2(2):81-90. doi:10.1093/ehjqcco/qcw005
    1. DuGoff EH, Canudas-Romo V, Buttorff C, Leff B, Anderson GF. Multiple chronic conditions and life expectancy: a life table analysis. Med Care. 2014;52(8):688-694. doi:10.1097/MLR.0000000000000166
    1. Michaud GF, Stevenson WG. Atrial fibrillation. N Engl J Med. 2021;384(4):353-361. doi:10.1056/NEJMcp2023658
    1. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi:10.1136/bmj.i4482
    1. Hayes SN, Kim ESH, Saw J, et al. ; American Heart Association Council on Peripheral Vascular Disease; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Stroke Council . Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018;137(19):e523-e557. doi:10.1161/CIR.0000000000000564
    1. de Lemos JA, Newby LK, Mills NL. A proposal for modest revision of the definition of type 1 and type 2 myocardial infarction. Circulation. 2019;140(22):1773-1775. doi:10.1161/CIRCULATIONAHA.119.042157
    1. McCarthy CP, Kolte D, Kennedy KF, Vaduganathan M, Wasfy JH, Januzzi JL Jr. Patient characteristics and clinical outcomes of type 1 versus type 2 myocardial infarction. J Am Coll Cardiol. 2021;77(7):848-857. doi:10.1016/j.jacc.2020.12.034
    1. Lambrakis K, French JK, Scott IA, et al. . The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): a randomized trial design. Am Heart J. 2019;208:11-20. doi:10.1016/j.ahj.2018.09.016
    1. Shah ASV, Sandoval Y, Noaman A, et al. . Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. BMJ. 2017;359:j4788. doi:10.1136/bmj.j4788

Source: PubMed

3
구독하다